Entropy Technologies LP Purchases Shares of 31,200 TG Therapeutics, Inc. (NASDAQ:TGTX)

Entropy Technologies LP bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 31,200 shares of the biopharmaceutical company's stock, valued at approximately $730,000.

Several other institutional investors have also bought and sold shares of the stock. Assenagon Asset Management S.A. acquired a new stake in shares of TG Therapeutics in the 2nd quarter valued at $8,698,000. Principal Financial Group Inc. lifted its holdings in TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock valued at $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Marshall Wace LLP acquired a new position in TG Therapeutics in the second quarter valued at about $36,501,000. Raymond James & Associates grew its stake in TG Therapeutics by 35.9% during the third quarter. Raymond James & Associates now owns 170,160 shares of the biopharmaceutical company's stock worth $3,980,000 after buying an additional 44,972 shares during the last quarter. Finally, New York State Teachers Retirement System acquired a new stake in shares of TG Therapeutics during the third quarter worth approximately $1,004,000. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Stock Down 4.2 %

Shares of TGTX stock traded down $1.30 on Friday, hitting $29.54. The stock had a trading volume of 3,274,962 shares, compared to its average volume of 3,708,598. TG Therapeutics, Inc. has a twelve month low of $10.98 and a twelve month high of $36.50. The company has a fifty day moving average price of $24.59 and a two-hundred day moving average price of $20.96. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company's revenue for the quarter was down 49.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.73 EPS. As a group, research analysts expect that TG Therapeutics, Inc. will post 0.17 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Sagar Lonial sold 5,000 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now owns 100,195 shares of the company's stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 10.50% of the company's stock.

Wall Street Analyst Weigh In

TGTX has been the topic of several recent analyst reports. B. Riley boosted their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a report on Wednesday, August 7th. The Goldman Sachs Group boosted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price for the company. Finally, HC Wainwright upped their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.